/AZN
AstraZeneca PLC
AZN • NYSEAZN • NYSE • Healthcare
$201.53-0.11%-0.23
$201.53-0.11%(-0.23)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
0Bearish
Risk
100Low Risk
Momentum
86Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
81.9%▲0.8pp
Revenue after COGS
Operating
23.4%▲4.9pp
After operating expenses
Net
17.5%▲4.4pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
26.5
Price vs earnings
EV/EBITDA
14.9
Enterprise value
FCF Yield
4.3%
Cash generation
Earnings Yield
3.8%
Inverse of P/E
Capital Efficiency
15
GoAI Quality ScoreFair
ROEReturn on Equity
21.1%Strong
ROAReturn on Assets
9.0%Strong
ROICReturn on Invested Capital
13.0%Strong
Financial Health
Current RatioWeak
0.94
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
1.21x
Debt repayment capacity (<3x)
Income QualityStrong
1.43
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Gross Profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B |
| Gross Margin | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% |
| Operating Income | $13.74B | $10.00B | $8.19B | $3.76B | $1.06B |
| Net Income | $10.26B | $7.04B | $5.96B | $3.29B | $112.00M |
| Net Margin | 17.5% | 13.0% | 13.0% | 7.4% | 0.3% |
| EPS | $6.60 | $2.27 | $3.81 | $2.12 | $0.08 |
Average Price Target
$105.50▼ 47.7% Downside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for AstraZeneca PLC, the average price target is $105.50, with a high forecast of $108.00 and a low forecast of $103.00. The average price target represents a 47.7% decrease from the current price of $201.53.
Highest
$108.00
Average
$105.50
Lowest
$103.00
Rating Distribution
Strong Buy
1
2%
Buy
19
46%
Hold
15
37%
Sell
6
15%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
UBS▲ Upgrade
Neutral→Buy
2025-02-13UBS▲ Upgrade
Sell→Neutral
2024-11-20Erste Group▲ Upgrade
Hold→Buy
2024-09-11TD Cowen● Maintain
Buy
2024-08-12Argus Research● Maintain
Buy
2024-05-30BMO Capital● Maintain
Outperform
2024-04-26Deutsche Bank▲ Upgrade
Sell→Hold
2024-04-16BMO Capital● Maintain
Outperform
2024-02-12Deutsche Bank▼ Downgrade
Buy→Hold
2024-02-08Jefferies▼ Downgrade
Buy→Hold
2024-01-03Earnings History & Surprises
BEAT RATE
56%
Last 18 quarters
AVG SURPRISE
+0.8%
EPS vs Estimate
BEATS / MISSES
10/7
1 met exactly
LATEST EPS
$2.12
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-2.8%
$2.12 vs $2.18
Q4 '25
+4.4%
$1.19 vs $1.14
Q3 '25
$1.09 vs $1.09
Q2 '25
+12.7%
$1.24 vs $1.10
Q1 '25
-1.9%
$1.05 vs $1.07
Q4 '24
+1.0%
$1.04 vs $1.03
Q3 '24
-17.5%
$0.99 vs $1.20
Q2 '24
-15.6%
$1.03 vs $1.22
Q1 '24
-7.6%
$0.73 vs $0.79
Q4 '23
+2.4%
$0.87 vs $0.85
Q3 '23
+13.7%
$1.08 vs $0.95
Q2 '23
-10.3%
$0.96 vs $1.07
No investor questions available.
Latest News
No news available